Poxel SA Asset Resilience Ratio
Poxel SA asset resilience ratio. Poxel SA (POXEL) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Poxel SA to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Poxel SA (2016–2023)
Asset resilience ratio of Poxel SA from 2016 to 2023. This chart shows how Poxel SA's Asset Resilience Ratio has changed over time. Read debt load of Poxel SA for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Poxel SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see POXEL current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Poxel SA maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Poxel SA Industry Peers by Asset Resilience Ratio
Compare Poxel SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Poxel SA Asset Resilience Ratio by Year (2016–2023)
Poxel SA asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for Poxel SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -1.78% | €-86.00K ≈ $-100.54K |
€4.82 Million ≈ $5.64 Million |
-1.23pp |
| 2022-12-31 | -0.56% | €-193.00K ≈ $-225.64K |
€34.71 Million ≈ $40.58 Million |
-13.43pp |
| 2021-12-31 | 12.87% | €7.07 Million ≈ $8.26 Million |
€54.89 Million ≈ $64.17 Million |
-62.78pp |
| 2020-12-31 | 75.65% | €49.23 Million ≈ $57.56 Million |
€65.08 Million ≈ $76.08 Million |
+23.02pp |
| 2019-12-31 | 52.63% | €38.05 Million ≈ $44.49 Million |
€72.30 Million ≈ $84.53 Million |
-37.59pp |
| 2016-12-31 | 90.22% | €45.38 Million ≈ $53.06 Million |
€50.30 Million ≈ $58.81 Million |
-- |
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more